Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › CagriSema

CagriSema

GLP-1 + amylin · s.c. · Novo Nordisk

Data cut 12 November 2026 · page built 16 November 2026 · 6 trial arms · 7 trials with results · 25 registered trials · see on the pipeline board

Summary

Also known as
cagrilintide + semaglutide
Mechanism
GLP-1 + amylin
Route
s.c.
Company
Novo Nordisk
Highest development stage
phase 3
Status (as of data cut)
Phase 3 (REDEFINE); filing 2026 verify
Next milestone
REDEFINE 3 (CV outcomes), REIMAGINE (T2D)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3; NDA under FDA review (submitted 18 December 2025)REDEFINE 1; REDEFINE 5; Novo Nordisk release, 18 Dec 2025
T2D3 positive phase 3Positive phase 3REDEFINE 2; REIMAGINE 1 (EASD 2026)
CV outcomes2 phase 3 ongoingREDEFINE 3 ongoingREDEFINE 3
CKD1 phase 2 / signalPhase 2 only
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
REDEFINE 1CagriSema 2.4/2.4 mgobesity683417−22.7 % vs −2.3 %
Δ −20.4 pp
−20.4 % vs −3.0 %
Δ −17.4 pp
—5.9 vs 3.511.8 vs 24.1——9.8 vs 6.1−9.9 vs −3.2verified
REDEFINE 2CagriSema 2.4/2.4 mgt2d681206−15.7 % vs −3.1 %
Δ −12.6 pp
−13.7 % vs −3.4 %
Δ −10.3 pp
−1.8 vs −0.48.4 vs 3.0———10.4 vs 12.9−6.5 vs −2.4verified
REDEFINE 5 (vs semaglutide 2.4 mg)CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg: −11.9 % (efficacy)obesity68164−18.4 %−16.9 %−1.12.010.0——4.0−10.0verified
REDEFINE 9CagriSema 1.0/1.0 mgobesity68—−21.0 % vs −2.0 %
Δ −19.0 pp
————————press release
REIMAGINE 1 (early T2D)CagriSema 2.4/2.4 mgt2d40189−14.3 % vs −2.8 %
Δ −11.5 pp
−14.3 % vs −2.8 %
Δ −11.5 pp
———————verified
REIMAGINE 5 (vs tirzepatide 5 mg)CagriSema 1.0/1.0 mg vs tirzepatide 5 mg (active)t2d60—−12.4 %—−1.7——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (23)
  • CagriSema 2.4/2.4 mg · weight_eff · Results, Efficacy, Body-Weight Reduction; Fig 1B
    On the basis of the trial-product estimand, the percent weight reduction was −22.7% with cagrilintide–semaglutide and −2.3% with placebo
  • CagriSema 2.4/2.4 mg · weight_tp · Table 2; Results, Efficacy
    the mean percent body-weight reduction at week 68 was −20.4% with cagrilintide–semaglutide and −3.0% with placebo
  • CagriSema 2.4/2.4 mg · ae_dc · Table 3; Results, Safety
    discontinued because of adverse events (5.9% vs. 3.6%, 2.6%, and 3.5%, respectively)
  • CagriSema 2.4/2.4 mg · sae · Table 3; Results, Safety
    Serious adverse events were reported in 9.8% of the participants receiving cagrilintide–semaglutide
  • CagriSema 2.4/2.4 mg · sbp · Table 2; Results, Additional End Points
    The mean reduction from baseline to week 68 in systolic blood pressure was −9.9 mm Hg with cagrilintide–semaglutide and −3.2 mm Hg with placebo
  • CagriSema 2.4/2.4 mg · disc_any · Results, Participants
    The percentage of participants still receiving the drug or placebo at week 68 was 88.2% in the cagrilintide–semaglutide group, 91.4% in the semaglutide group, 87.7% in the cagrilintide group, and 75.9% in the placebo gro
  • CagriSema 2.4/2.4 mg · weight_tp · Results, Body Weight (p.652); also Table 2 row 'Percent chan
    For the treatment-policy estimand, the estimated mean change in body weight from baseline to week 68 (the first primary end point) was –13.7% with cagrilintide–semaglutide, as compared with –3.4% with placebo (estimated
  • CagriSema 2.4/2.4 mg · weight_eff · Results, Body Weight (p.652); Fig. 1B; full table in Table S
    For the trial-product estimand, the change in body weight was –15.7% with cagrilintide–semaglu- tide and –3.1% with placebo (estimated differ- ence, –12.6 percentage points; 95% CI, –13.4 to –11.7)
  • CagriSema 2.4/2.4 mg · hba1c · Results, Glycemic-Related End Points (p.654); Table 2 row 'C
    For the treatment-policy estimand, cagrilintide– semaglutide led to a greater mean reduction in the glycated hemoglobin level from baseline to week 68, as compared with placebo (–1.8 per- centage points vs. –0.4 percenta
  • CagriSema 2.4/2.4 mg · sbp · Table 2 (p.652), confirmatory secondary end point; also Resu
    Change in systolic blood pressure — mm Hg –6.5 –2.4 –4.1 (–6.0 to –2.1)
  • CagriSema 2.4/2.4 mg · ae_dc · Table 3 (p.656) row 'Leading to permanent discontinuation —
    Leading to permanent discontinuation Any adverse event 76 (8.4) 97 7.6 9 (3.0) 13 3.1
  • CagriSema 2.4/2.4 mg · sae · Table 3 (p.656) row 'Serious'; Results, Safety (p.655)
    Serious 94 (10.4) 138 10.8 39 (12.9) 51 12.1
  • CagriSema 2.4/2.4 mg · weight_eff · Results, MRI sub-study
    CagriSema reduced BW vs pbo (2.4 mg/2.4 mg: −14.3%; 1.0 mg/1.0 mg: −11.2%; pbo: −2.8%;
  • CagriSema 2.4/2.4 mg · weight_eff · Table 2
    Change in bodyweight† −18·4% −11·9% −6·5 (−8·4 to −4·6) <0·0001
  • CagriSema 2.4/2.4 mg · weight_tp · Results, paragraph 4 (treatment policy estimand)
    had a mean change in bodyweight of –16·9% (0·7) versus –11·1% (0·7) for semaglutide
  • CagriSema 2.4/2.4 mg · ae_dc · Results, paragraph 10; Table 3
    cagrilintide–semaglutide group (three [2%] participants) and the semaglutide group (four [2%]; table 3)
  • CagriSema 2.4/2.4 mg · disc_any · Summary, Findings; Results paragraph 1
    17 (10%) participants discontinued cagrilintide–semaglutide and ten (6%) discontinued semaglutide.
  • CagriSema 2.4/2.4 mg · sae · Results, paragraph 10; Table 3
    Serious adverse events were reported in six (4%) participants receiving cagrilintide–semaglutide and 11 (7%) receiving semaglutide
  • CagriSema 2.4/2.4 mg · hba1c · Table 2
    Change in HbA1c, %§ −1·1 −1·0 −0·1 (−0·2 to 0·0) 0·017
  • CagriSema 2.4/2.4 mg · sbp · Table 2
    Change in systolic blood pressure, mmHg§ −10·0 −5·2 −4·9 (−7·7 to −2·0) 0·0008
  • CagriSema 1.0/1.0 mg · weight_eff · company announcement
    CagriSema 1.0 mg/1.0 mg was superior to tirzepatide 5 mg for weight loss
  • CagriSema 1.0/1.0 mg · hba1c · company announcement
    1.71% (CagriSema) vs. 1.67% (tirzepatide) – non-inferior
  • CagriSema 1.0/1.0 mg · weight_eff · company announcement
    CagriSema 1.0 mg/1.0 mg provided a weight reduction of 21.0% versus 2.0%

Outcome trials

Ongoing outcome trials

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
REDEFINE 3CagriSemaObesity + established CVD
Obesity + established CVD, with or without T2D
3-point MACE7101active not recruiting2027-09-01NCT05669755

Registered trials (25)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
REDEFINE
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
HypertensionPhase 3not yet recruiting2026-11 → 2028-061408not yet recruitingNCT07919405
NCT07817251
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
T2DPhase 3recruiting2026-09 → 2027-06210recruitingNCT07817251
REIMAGINEYOUNG
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
T2DPhase 3recruiting2026-08 → 2029-0980recruitingNCT07282613
RENEW 4
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
ObesityPhase 3recruiting2026-08 → 2027-05285recruitingNCT07745504
NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
ObesityPhase 3recruiting2026-05 → 2028-022500recruitingNCT07564414
NCT07253285
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
ObesityPhase 3recruiting2026-01 → 2030-03460recruitingNCT07253285
RENEW 1
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
ObesityPhase 3active not recruiting2025-11 → 2027-05300active not recruitingNCT07220642
RENEW 2
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ObesityPhase 3active not recruiting2025-11 → 2027-05330active not recruitingNCT07220759
NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
ObesityPhase 3active not recruiting2025-06 → 2027-03609active not recruitingNCT07011667
NCT06780449
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
ObesityPhase 3active not recruiting2025-02 → 2028-08400active not recruitingNCT06780449
NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NeurologyPhase 2completed2025-01 → 2026-06142Completed; results not in the atlas yetNCT06797869
REIMAGINE 5
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
T2DPhase 3completed2024-11 → 2026-061023Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06534411
NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
ObesityPhase 3completed2024-06 → 2026-04300Completed; results not in the atlas yetNCT06388187
NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
OtherPhase 2completed2024-05 → 2025-11270Completed; results not in the atlas yetNCT06409130
NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
CKDPhase 2completed2024-04 → 2025-09626Completed; results not in the atlas yetNCT06131372
REIMAGINE 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
T2DPhase 3completed2024-03 → 2025-09274Completed; results not in the atlas yetNCT06323161
REIMAGINE 1
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
T2DPhase 3completed2024-03 → 2025-10189Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06323174
REIMAGINE 4
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
T2DPhase 3completed2024-01 → 2026-031024Completed; results not in the atlas yetNCT06221969
REDEFINE 4
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
ObesityPhase 3completed2023-11 → 2025-12809Weight non-inferiority vs tirzepatide 15 mg not met: −20.2 % vs −23.6 % (treatment-regimen), −23.0 % vs −25.5 % (efficacy); topline press release, Feb 2026NCT06131437
REIMAGINE 2
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
T2DPhase 3completed2023-09 → 2025-112734Completed; results not in the atlas yetNCT06065540
REDEFINE 6
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
ObesityPhase 3completed2023-08 → 2025-01300Completed; results not in the atlas yetNCT05996848
REDEFINE 5
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
ObesityPhase 3completed2023-04 → 2025-01331Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05813925
REDEFINE 3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
CV outcomesPhase 3active not recruiting2023-03 → 2027-097101NCT05669755
REDEFINE 2
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
ObesityPhase 3completed2023-02 → 2025-011200Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05394519
REDEFINE 1
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
ObesityPhase 3active not recruiting2022-11 → 2024-103400active not recruitingNCT05567796

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: CagriSema. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/cagrisema/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.